# Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

> **NCT02903524** · PHASE4 · UNKNOWN · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin Hydrochloride Liposome injection and cyclophosphamide
- **DRUG:** pirarubicin and cyclophosphamide

## Key facts

- **NCT ID:** NCT02903524
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2018-09
- **Final completion:** 2018-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903524, "Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02903524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*